Consistent Glycemic Efficacy and Safety of Concomitant Use of iGlarLixi and Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Type 2 Diabetes-A Patient-Level Pooled Analysis

被引：0
|
作者：
Giorgino, Francesco
Guja, Cristian
Davies, Melanie J.
Aydin, Hasan
Lauand, Felipe
Souhami, Elisabeth
Melas-Melt, Lydie
Aroda, Vanita R.
Rosenstock, Julio
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-773-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
773-P
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Hypothetical intervention of sodium-glucose cotransporter-2 inhibitors on renal outcome in type 2 diabetes
    Takeuchi, Masato
    Kawakami, Koji
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 131 - 132
  • [42] Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes
    Arakaki, Richard F.
    POSTGRADUATE MEDICINE, 2016, 128 (04) : 409 - 417
  • [43] Effectiveness and Safety of Sodium-Glucose Cotransporter-2 Inhibitor Continuation in Patients With Type 2 Diabetes and Late-Stage Chronic Kidney Disease
    Denny, Olivia
    Albanese, Nicole P.
    Meaney, Calvin J.
    Siwarski, Nicole E.
    Monte, Scott V.
    JOURNAL OF PHARMACY TECHNOLOGY, 2025, 41 (02) : 65 - 71
  • [44] Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
    Chilton, Robert J.
    DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 16 - 29
  • [45] Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes
    Suissa, Karine
    Schneeweiss, Sebastian
    Douros, Antonios
    Yin, Hui
    Patorno, Elisabetta
    Azoulay, Laurent
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 192
  • [46] BUDGET IMPACT ANALYSIS OF ADOPTING SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR FOR TREATMENT OF TYPE 2 DIABETES MELLITUS IN MINISTRY OF HEALTH MALAYSIA
    Idrus, N.
    VALUE IN HEALTH, 2022, 25 (01) : S111 - S112
  • [47] Risk of erythrocytosis associated with combined use of sodium-glucose cotransporter-2 inhibitors and testosterone replacement therapy in persons with type 2 diabetes
    Schumacher, K.
    Gemoets, D. E.
    Gosmanov, A. R.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 365 : S349 - S349
  • [48] Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
    Henry, Robert R.
    Thakkar, Payal
    Tong, Cindy
    Polidori, David
    Alba, Maria
    DIABETES CARE, 2015, 38 (12) : 2258 - 2265
  • [49] THE DEVELOPMENT OF FOURNIER'S GANGRENE IN A PATIENT WITH A HISTORY OF SCROTAL ABSCESS AND UNDERLYING TYPE 2 DIABETES TREATED WITH A SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR
    Sevilla, S.
    McCaleb, J.
    Alkasir, A.
    Currie, D.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2022, 70 (01) : 298 - 299
  • [50] Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
    Berg, David D.
    Wiviott, Stephen D.
    Scirica, Benjamin M.
    Gurmu, Yared
    Mosenzon, Ofri
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Johanson, Per
    Johansson, Peter A.
    Langkilde, Anna Maria
    Raz, Itamar
    Braunwald, Eugene
    Sabatine, Marc S.
    CIRCULATION, 2019, 140 (19) : 1569 - 1577
12345